How and where to order Propranolol (Inderal, Inderal-LA, Innopran-XL) 10 mg, 20 mg, 40 mg, 80 mg tablets or capsules online:
INNOPRAN-XL (PROPRANOLOL HYDROCHLORIDE): PRECAUTIONS (see "References")
Propranolol Hydrochloride (InnoPran-XL) capsules should be used with caution in patients with impaired hepatic or renal function. InnoPran-XL is not indicated for the treatment of hypertensive emergencies.
Beta-adrenergic receptor blockade can cause reduction of intraocular pressure. Patients should be told that InnoPran-XL may interfere with the glaucoma screening test. Withdrawal may lead to a return of intraocular pressure.
Caution should be exercised when administering InnoPran-XL (Propranolol) to patients with underlying skeletal muscle disease. Isolated cases of exacerbation of myopathy and myotonia have been reported.
Risk of Anaphylactic Reaction
While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
Clinical Laboratory Tests
In patients with hypertension, use of InnoPran-XL (Propranolol) capsules has been associated with elevated levels of serum potassium, and serum transaminases and alkaline phosphatase. In severe heart failure, the use of propranolol has been associated with increases in blood urea nitrogen.
Carcinogenesis, Mutagenesis, Impairment of Fertility
In dietary administration studies in which mice and rats were treated with InnoPran-XL (Propranolol HCl) capsules for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis. On a body surface area basis, this dose in the mouse and rat is, respectively, about equal to and about twice the maximum recommended human oral daily dose (MRHD) of 640 mg propranolol HCl. In a study in which both male and female rats were exposed to propranolol HCl in their diets at concentrations of up to 0.05% (about 50 mg/kg body weight and less than the MRHD), from 60 days prior to mating and throughout pregnancy and lactation for 2 generations, there were no effects on fertility. Based on differing results from Ames tests performed by different laboratories, there is equivocal evidence for a genotoxic effect of propranolol HCl in bacteria (S. typhimurium strain TA 1538).
Pregnancy Category C
In a series of reproductive and developmental toxicology studies, InnoPran-XL (Propranolol Hydrochloride) was given to rats by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the MRHD on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (deaths). Propranolol HCl also was administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose). No evidence of embryo or neonatal toxicity was noted.
There are no adequate and well controlled studies in pregnant women. Intrauterine growth retardation, small placentas, and congenital anomalies have been reported for neonates whose mothers received propranolol during pregnancy. Neonates whose mothers received propranolol HCl at parturition have exhibited bradycardia, hypoglycemia, and/or respiratory depression. Adequate facilities for monitoring such infants at birth should be available. InnoPran-XL (Propranolol Hydrochloride) capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Propranolol is excreted in human milk. Caution should be exercised when InnoPran-XL is administered to a nursing woman.
Safety and effectiveness of propranolol in pediatric patients have not been established.
Clinical studies of Propranolol (InnoPran-XL) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
InnoPran-XL prescribing information
Disclaimer: Please note, this website is not an online pharmacy, drugstore and related online pharma shop. It does not sell, supply or advertise any prescription and OTC drugs, medications, other goods and services. All reviews, links, lists, databases, texts, and other content on the website are provided free and only for informational and educational purposes. Medical content on this website, including drug names, indications, contraindication, side effects, categories, classifications, forms, doses, prices, other health and pharmaceutical information are taken only from trusted and authoritative professional sources (see "References"), reviewed and prepared by our licensed experts, content inspectors and editors.
You should always consult your doctor or other healthcare professional before using any medication. This website, our staff and support do not provide own medical instructions and advices.
All brands and trade names appearing on the website are registered trademarks of their respective companies.
Remember that buying drugs and medicines online is a responsibility only of customers, sellers and suppliers regarding existing legislation in their jurisdictions.
Share us in social media:
Copyright © 2014-2020 Propranolol-Tablets.com, a division of Pharma-Doctor.com pharmaceutical network. All rights reserved.
Home Page |
Cookies Policy |
Terms of Service |